Chimerix, Inc.

CMRX

Market cap $801M

As of April 7, 2025, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Investing in biotech can be highly rewarding but is fraught with risks; understanding past catalysts can help investors make informed decisions and minimize downside risk. CervoMed Inc. surged over 300% in Q1 2025 due to positive Phase 2b trial results for its lead drug candidate, neflamapimod despite earlier setbacks. Chimerix Inc. gained over 144% after announcing an acquisition by Jazz Pharmaceuticals and positive FDA feedback on its lead drug candidate, dordaviprone.

New Drug Application (NDA) for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma Under Review with Prescription Drug User Fee Act (PDUFA) Action Date of August 18, 2025

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Chimerix, Inc. (NasdaqGM: CMRX) to Jazz Pharmaceuticals plc. (NasdaqGS: JAZZ). Under the terms of the proposed transaction, shareholders of Chimerix will receive $8.55 in cash for each share of Chimerix that they own. KSF is seeking to determine whether this consideration and the process that led to.

DURHAM, N.C., March 07, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on March 2, 2025, the Compensation Committee of Chimerix's Board of Directors granted an inducement award to a new employee of non-statutory stock options to purchase up to a total of 70,000 shares of Chimerix's common stock. The Compensation Committee of Chimerix's Board of Directors approved the award as an inducement material to the new employee's employment in accordance with Nasdaq Listing rule 5635(c)(4).

NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Chimerix, Inc. (NASDAQ: CMRX) to Jazz Pharmaceuticals plc for $8.55 per share in cash is fair to Chimerix shareholders.

Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals are included in this Analyst Blog.

CMRX and JAZZ are in the spotlight this week following an acquisition agreement.

JAZZ's acquisition of CMRX is set to add a rare high-grade brain tumor drug currently under the FDA's review. The deal is likely to be closed by June 2024.

NEW YORK , March 5, 2025 /PRNewswire/ -- Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Chimerix, Inc. (NASDAQ: CMRX ), relating to the proposed merger with Jazz Pharmaceuticals.